

## **CURRICULUM PROF: FERDINANDO DE VITA**

Degree in Medicine and Surgery at the University "Federico II" of Naples with 110/110, praise and dignity of the press discussing the thesis: "Evaluation of the PAC scheme in the treatment of advanced ovarian cancer" (1987) .

Qualification to practice as a physician-surgeon at the University of Naples with a score of 90/90 (1988).

Specialization in Oncology at the University "Federico II" of Naples with 70/70 cum laude discussing the thesis: "The soluble receptor for Interleukin-2 (sIL-2R) in solid tumors" (1990).

Practical theoretical training for specific training in general medicine according to the modalities and norms established by the D.I. 10/10/1988 with the vote of 50/50 (1990-1991).

Visiting Researcher at the Laboratory of Immunochemistry of the Department of Biomedical Sciences and Human Oncology of the University of Bari (1992).

Stage at the Bethesda National Cancer Institute "New Trends in Oncology" (March 31-April 3, 1992).

Therapeutic Area Manager Oncology for Bristol-Myers Squibb from 06/29/1993 to 01/10/1993

Stage "Mechanisms of signal translation by cytokines" at the School for Biotechnology and Experimentation in Oncology of the University of Genoa (November 27 - December 1, 1995).

PhD in Broncopneumology discussing the thesis "The immunological characterization of non-microcytoma lung carcinoma: analysis of the expression of soluble lymphocytic antigens and cytokines" (1996).

Clinical Exchange Program UTMD Anderson Cancer Center in Houston (8-12 April 1996).

Stage Yale University School of Medicine - Departments of Surgery and Internal Medicine (October 27-30, 1997).

Assistant Professor of Medical Oncology (MED 06) at the University of Campania "Luigi Vanvitelli" (1999).

Associate Professor of Medical Oncology (MED06) at the "Luigi Vanvitelli" University of Campania from November 2014 to today.

Director of the School of Specialization in Medical Oncology of the "Luigi Vanvitelli" University of Campania. 2014 to date.

Member of the AIOM (Italian Association of Medical Oncology) and of the ESMO (European Society of Medical Oncology).

Member of the Board of Directors of the Mediterranean Oncology Society (2009-2010).

Vice-President of the Oncology Group of Southern Italy (GOIM) 2014-2017.

President-Elect of the Oncology Group of Southern Italy (GOIM) 2017-2019

## **SCIENTIFIC ACTIVITY**

Member of the Steering Committee and National Coordinator of the Clinical Surgery plus Epirubicin 5-fluorouracil and etoposide versus surgery alone as adjuvant treatment in a radically resected gastric cancer: a randomized phase 3 trial (Trial GOIM 9602) from 24/02/2000 to 23/02 / 2006. GOIM Promoter.

Study Coordinator and Principal Investigator of the National Clinical Trial "Weekly docetaxel and capecitabine as a first line of metastatic gastric cancer A phase II trial" from 10/03/2004 to 12/15/2005. Promoter University of Campania "Luigi Vanvitelli".

Study Coordinator and Principal Investigator of the Clinical Study Epirubicin, Capecitabine and Cisplatin vs Docetaxel and 5-Fluorouracil as first line therapy of metastatic gastric or gastroesophageal cancer: a multicenter randomized phase II trial (Trial GOIM 2701) from 28/02/2008 to 03 / 03/2011. GOIM Promoter.

Member of the Steering Committee, National Study Coordinator and Principal Investigator of the Clinical Study Induction chemotherapy with FOLFOX-4 and Cetuximab followed by Radiotherapy and Cetuximab as preoperative treatment in locally advanced esophageal cancer: a multicenter italian phase II trial from 10/01/2006 to 17 / 12/2010. Promoter University of Campania "Luigi Vanvitelli".

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the National Clinical Study of the study "Sorafenib Treatment modalities for HEPatoceLLular carcinoma patients in itAly" .Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy (STELLA) from 23.02.2012 to 16.04.2014. Promoter of the study: BAYER.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the National Observational Study "Natural History of Malignant Bone Disease in Gastric Cancer: a multicenter bone metastasis survey" from 24/02/2012 to 11/04/2013.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the International Clinical Trial First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1 ) from 18/03/2013 to 13/01/2016. Promoter of the study: AMGEN.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the International Clinical Study A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (BO25114-JACOB Trial) from 19/03/2013 to 17/03/2017. Promoter of the study: ROCHE

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the Phase IIIb International Clinical Study Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2 -Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. (BO27798-HELOISE) from 09.05.2014 to 29.11.2016. Promoter of the study: ROCHE.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the International Clinical Study A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric / Gastroesophageal Junction / Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors from 02/19/2014 to 06/15/2015. Promoter of the study: AMGEN.

Co-Chairman and Principal Investigator of the National Retrospective Observational Study on the use of Ramucirumab in patients with gastric carcinoma and progressively metastatic gastroesophageal junction after a first line of therapy with platinum derivatives and fluoropyrimidine from 11.11.2015 to 28.10.2016.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the National Study "Analysis of the expression of enzymes related to glycolysis aerobia in gastric carcinoma and possible clinical impact on anti-angiogenic treatment with ramucirumab + second-line chemotherapy in metastatic disease" from 05/05/2016. Promoter: University of Urbino / Mario Negri Institute, Milan.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the International Clinical Study A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants with Stomach Cancer (Trial RAINFALL) from 24.03.2015 to 12.10.2016. Promoter of the study: LILLY.

Principal Investigator of the Clinical Study Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer (GIP-2) (EudraCT: 2013-003080-5) from 03.08.2015 to today. Promoter of the study: Pisana Hospital-University.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the International Clinical Study Study of Pembrolizumab (MK-3475).

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the International Clinical Study A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation ( BMS CA 209-9DX) from 22.12.2017 to today. Promoter: BMS.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the International Clinical Study A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab or Placebo as First-line Treatment in Participants with HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811) from 07.03.2017 to today. Promoter: MERCK.

Principal Investigator for the University of Campania "Luigi Vanvitelli" of the National Clinical Study "Modified Schedule of Nab-Paclitaxel and Gemcitabine in maintenance after standard treatment of induction in the first line with Nab-Paclitaxel and Gemcitabine in patients with metastatic pancreatic tumor ECOG PS 2 : an open-ended randomized phase II study of the Oncological Group of Southern Italy (GOIM 16004) from 15.11.2017 to today. GOIM Promoter.

## PAPERS

1. Catalano G, Della Vittoria Scarpati M, De Vita F, Federico P, Guarino G, Perrelli A, Rossi V. The role of "bioelectrical impedance analysis" in the evaluation of the nutritional status of cancer patients. *Adv Exp Med Biol.* 1993;348:145-8.
2. Orditura M, Ducceschi V, De Vita F, Santangelo L, Ciaramella F, Catalano G, Iacono A. Ventricular repolarization time indexes following anthracycline treatment. *Sarubbi B, Heart Vessels.* 1997;12(6):262-6.
3. Orditura M, De Vita F, Catalano G. Adult Wilms' tumor: a case report. *Cancer.* 1997 Nov 15;80(10):1961-5.

4. De Lucia D, De Vita F, Orditura M, Renis V, Belli A, Conte M, di Grazia M, Iacoviello L, Donati MB, Catalano G. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. *Tumori*. 1997 Nov-Dec;83(6):948-52.
5. De Vita F, Infusino S, Auriemma A, Orditura M, Catalano G. Circulating levels of soluble intercellular adhesion molecule-1 in non-small cell lung cancer patients. *Oncol Rep*. 1998 Mar-Apr;5(2):393-6.
6. Orditura M, De Vita F, Sarubbi B, Ducceschi V, Auriemma A, Infusino S, Iacono A, Catalano G. Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients. *Oncol Rep*. 1998 May-Jun;5(3):645-7.
7. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. *Oncol Rep*. 1998 May-Jun;5(3):649-52.
8. De Vita F, Turitto G, di Grazia M, Frattolillo A, Catalano G. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer. *Tumori*. 1998 Jan-Feb;84(1):33-8.
9. De Vita F, Orditura M, Infusino S, Auriemma A, Catalano G. Increased serum levels of tumor necrosis factor-alpha are correlated to soluble intercellular adhesion molecule-1 concentrations in non-small cell lung cancer patients. *Int J Mol Med*. 1998 Mar;1(3):605-8.
10. Orditura M, De Vita F, Roscigno A, Auriemma A, Infusino S, Catalano G. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors. *Int J Mol Med*. 1998 Jul;2(1):75-9.
11. De Vita F, Orditura M, Auriemma A, Infusino S, Catalano G. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. *J Exp Clin Cancer Res*. 1998 Dec;17(4):413-7.
12. The Italian Group for Antiemetic Research. Transferability to clinical practice of the results of controlled trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. *Ann Oncol* 1998; 9 : 759-65.
13. De Vita F, Orditura M, Auriemma A, Infusino S, Catalano G. A pilot study of adjuvant chemotherapy with double modulation of 5-fluorouracil by methotrexate and leucovorin in gastric cancer patients. *Panminerva Med*. 1999 Mar;41(1):35-8.

14. Comella P, Casaretti R, De Vita F, Avallone A, Orditura M, Petrillo A, Gravina A, Faranda A, Comis S, Comella G, Catalano G. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. *Ann Oncol.* 1999 Aug;10(8):915-21.
15. Orditura M, De Vita F, Roscigno A, Infusino S, Auriemma A, Iodice P, Ciaramella F, Abbate G, Catalano G. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review). *Oncol Rep.* 1999 Nov-Dec;6 (6):1357-62.
16. De Vita F, Orditura M, Galizia G, Romano C, Infusino S, Auriemma A, Lieto E, Catalano G. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. *Cancer.* 1999 Nov 15;86(10):1936-43.
17. Caponigro F, Avallone A, McLeod H, Cartenì G, De Vita F, Casaretti R, Morsman J, Blackie R, Budillon A, De Lucia L, Gravina A, Catalano G, Comella P, Comella G. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. *Clin Cancer Res.* 1999 Dec;5(12):3948-55.
18. Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. *Int J Oncol.* 2000 Jan;16(1):149-54.
19. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. *Chest.* 2000 Feb;117(2):365-73.
20. De Vita F, Orditura M, Galizia G, Romano C, Lieto E, Iodice P, Tuccillo C, Catalano G. Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. *Oncol Rep.* 2000 Mar-Apr;7(2):357-61.
21. Orditura M, De Vita F, Belli A, Ciaramella F, Musicò M, Ferrigno A, Formato R, Abbate G, Diadema MR, Catalano G. Efficacy and safety profile of amifostine in the preoperative combined therapy of esophageal cancer patients. *Oncol Rep.* 2000 Mar-Apr;7(2):397-400.
22. Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi FP, De Lena M. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. *J Urol.* 2000 Jul;164(1):53-6.

23. Comella P, De Vita F, De Lucia L, Casaretti R, Avallone A, Orditura M, Rivellini F, Palmeri S, Catalano G, Comella G. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group. *Ann Oncol.* 2000 Apr;11(4):461-8.
24. Comella P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, Farris A, Ianniello GP, Lorusso V, Avallone A, Cartenì G, Leo SS, Catalano G, De Lena M, Comella G. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. *Ann Oncol.* 2000 Oct;11(10):1323-33.
25. Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, De Cataldis G, Catalano G. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. *Cancer Immunol Immunother.* 2000 Dec;49(10):530-6.
26. De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. *J Interferon Cytokine Res.* 2001 Jan;21(1):45-52.
27. De Vita F, Orditura M, Martinelli E, Moraca L, De Chiara A, Catalano G. The new European gold standard treatment for rectum cancer. *Tumori.* 2000 Sep-Oct;86:26-9.
28. Ianniello GP, Orditura M, Rossi A, De Vita F, Maiorino L, Carrozza F, Manzione L, Catalano G. Gemcitabine plus epirubicin in advanced pancreatic cancer: a phase II multicenter trial. *Oncol Rep.* 2001 Sep-Oct;8(5):1111-5.
29. De Vita F, Orditura M, Infusino S, Martinelli E, Merola MC, Morgillo F, Cosenza A, Di Martino N, Del Genio A, Catalano G. Preoperative chemo-radiotherapy for carcinoma of the esophagus. *Tumori.* 2001 Jul-Aug;87(4):24-7.
30. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. *Clin Immunol.* 2002 Feb;102(2):169-78.

31. Comella P, Casaretti R, Crucitta E, De Vita F, Palmeri S, Avallone A, Orditura M, De Lucia L, Del Prete S, Catalano G, Lorusso V, Comella G. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. *Br J Cancer*. 2002 Jun 17;86(12):1871-5.
32. Comella P, Crucitta E, De Vita F, De Lucia L, Farris A, Del Gaizo F, Palmeri S, Iannelli A, Mancarella S, Tafuto S, Maiorino L, Buzzi F, De Cataldis G; Associated Institutions of the Southern Italy Cooperative Oncology Group. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. *Ann Oncol*. 2002 Jun;13(6):866-73.
33. De Vita F, Di Martino N, Orditura M, Cosenza A, Galizia G, Del Genio A, Catalano G. Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study. *Chest*. 2002 Oct;122(4):1302-8.
34. Orditura M, De Vita F, Catalano G, Infusino S, Lieto E, Martinelli E, Morgillo F, Castellano P, Pignatelli C, Galizia G. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. *J Interferon Cytokine Res*. 2002 Nov;22(11):1129-35.
35. Galizia G, Lieto E, Ferraraccio F, Castellano P, De Vita F, Orditura M, Romano C, Pignatelli C. A true splenic cyst producing carbohydrate antigen 19-9 and cancer antigens 50 and 125, but not interleukin 10. *Dig Surg*. 2003;20(1):71-4.
36. Comella P, Farris A, Lorusso V, Palmeri S, Maiorino L, De Lucia L, Buzzi F, Mancarella S, De Vita F, Gambardella A. Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma. *Br J Cancer*. 2003 Sep 15;89(6):992-6.
37. Ciardiello F, De Vita F, Orditura M, De Placido S, Tortora G. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. *Expert Opin Emerg Drugs*. 2003 Nov;8(2):501-14.
38. Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). *Anticancer Res*. 2003 Sep-Oct;23(5b):4219-22.

39. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. *Cancer*. 2004 Jan 15;100(2):270-8.
40. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. *Clin Cancer Res*. 2004 Jan 15;10(2):784-93.
41. De Vita F, Orditura M, Galizia G, Ciardiello F, Catalano G. Author reply. *Cancer*. 2004 Jul 15; 101(2):432-3.
42. Ciardiello F, De Vita F, Orditura M, Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. *Curr Opin Oncol*. 2004 Mar;16(2):130-5.
43. Galizia G, Lieto E, Ferraraccio F, Orditura M, De Vita F, Castellano P, Imperatore V, Romano C, Ciardiello F, Agostini B, Pignatelli C. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. *Clin Cancer Res*. 2004 May 15;10 (10):3490-9.
44. Orditura M, Quaglia F, Morgillo F, Martinelli E, Lieto E, De Rosa G, Comunale D, Diadema MR, Ciardiello F, Catalano G, De Vita F. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). *Oncol Rep*. 2004 Sep;12(3):549-56.
45. Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V, Romano C, Vollaro M, Agostini B, Pignatelli C, De Vita F. Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. *Dis Colon Rectum*. 2004 Nov;47(11):1904-14.
46. Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. *Clin Cancer Res*. 2005 Feb 1;11(3):1268-76.
47. Comella P, Massidda B, Filippelli G, Palmeri S, Natale D, Farris A, De Vita F, Buzzi F, Tafuto S, Maiorino L, Mancarella S, Leo S, Lorusso V, De Lucia L, Roselli M. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFUFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFUFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. *Ann Oncol*. 2005 Jun;16(6):878-86. Epub 2005 Apr 18.



48. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. *Br J Cancer*. 2005 May 9;92(9):1644-9.
49. De Vita F, Orditura M, Ciardiello F, Catalano G. Adjuvant chemotherapy of gastric cancer: which regimens? *Ann Oncol*. 2005 May;16; 4:102-105.
50. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. *Ann Oncol*. 2005 May;16; 4:61-68.
51. De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, Iannace C, Ianniello GP, De Vita F, Ficorella C, Farris A, Pistillucci G, Gemini M, Cortesi E, Adamo V, Gebbia N, Palmeri S, Gallo C, Perrone F, Persico G, Bianco AR. Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. *Br J Cancer*. 2005 Oct 17;93(8):896-904.
52. Carlomagno C, Orditura M, Pepe S, De Vita F, Romano C, Ciardiello F, Ferrara C, Martinelli E, Bianco R, Aurilio G, D'Agostino D, Tortora G, Catalano G, De Placido S. Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study. *Am J Clin Oncol*. 2006 Feb;29(1):85-9.
53. Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V, La Manna G, Pinto M, Ciardiello F, La Mura A, De Vita F. p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. *J Surg Oncol*. 2006 Mar 1;93(3):241-52.
54. Ciardiello F, De Vita F, Orditura M, Comunale D, Galizia G. Cetuximab in the treatment of colorectal cancer. *Future Oncol*. 2005 Apr;1(2):173-81.
55. Galizia G, Lieto E, Ferraraccio F, De Vita F, Castellano P, Orditura M, Imperatore V, La Mura A, La Manna G, Pinto M, Catalano G, Pignatelli C, Ciardiello F. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. *Ann Surg Oncol*. 2006 Jun;13(6):823-35.
56. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. *Br J Cancer*. 2006 Jun 5;94(11):1604-9.
57. Orditura M, Martinelli E, Galizia G, Carlomagno C, Aurilio G, Vecchione L, Lieto E, De Placido S, Catalano G, Ciardiello F, De Vita F. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. *Ann Oncol*. 2006 Oct;17(10):1529-32.

58. Orditura M, Lieto E, Ferraraccio F, De Cataldis G, Troiani T, Castellano P, Catalano G, Ciardiello F, Galizia G, De Vita F. Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. *World J Surg Oncol*. 2007 Apr 22;5:42.
59. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. *World J Surg*. 2007 Jul;31(7):1458-68.
60. De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, Montemurro F, Carteni G, Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G; Gruppo Oncologico Italia Meridionale. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). *Ann Oncol*. 2007 Aug;18(8):1354-8.
61. Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T, Imperatore V, Ciardiello F. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. *Oncogene*. 2007 May 28;26(25):3654-60.
62. De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. *Ann Oncol*. 2007 Jun;18;6:120-3.
63. Orditura M, Martinelli E, Galizia G, Vitiello F, Fasano M, Muto P, Ciardiello F, De Vita F. Chemoradiotherapy as adjuvant treatment of gastric cancer. *Ann Oncol*. 2007 Jun;18; 6:133-5.
64. Schettino C, Bareschino MA, Monaco K, Orditura M, De Vita F, Ciardiello F. Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): A case report. *Targeted Oncology* 2007; 2: 253-257.
65. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. *Ann Surg Oncol*. 2008 Jan;15(1):69-79.
66. Iovino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T, Diadema MR, Aurilio G, Santabarbara G, Ruggiero R, Belli C, Irlandese E, Fasano M, Ciardiello F, Procaccini E, Lo Schiavo F, Catalano G, De Vita F. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. *Cancer Invest*. 2008 Apr-May;26(3):250-5.
67. De Vita F, Vecchione L, Galizia G, Di Martino N, Fabozzi T, Catalano G, Ciardiello F, Orditura M. Perspectives in adjuvant therapy of gastric cancer. *Oncology*. 2009;77; 1:38-42..

68. Orditura M, De Vita F, Galizia G, Lieto E, Vecchione L, Vitiello F, Martinelli E, Ciardiello F. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. *Oncol Rep.* 2009 Apr;21(4):1023-8.
69. Vecchione L, Orditura M, Ciardiello F, De Vita F. Novel investigational drugs for gastric cancer. *Expert Opin Investig Drugs.* 2009 Jul;18(7):945-55.
70. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. *Clin Exp Immunol.* 2009 Oct;158(1):1-9.
71. Galizia G, Orditura M, Ferraraccio F, Castellano P, Pinto M, Zamboli A, Cecere S, De Vita F, Pignatelli C, Lieto E. The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery. *World J Surg.* 2009 Dec;33(12):2704-13.
72. Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E, Vecchione L, Romano A, Martinelli E, Renda A, Ferraraccio F, Del Genio A, Ciardiello F, Galizia G. Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. *Arch Surg.* 2010 Mar;145(3):233-8.
73. Zacchia M, Vilasi A, Capasso A, Morelli F, De Vita F, Capasso G. Genomic and proteomic approaches to renal cell carcinoma. *J Nephrol.* 2011 Mar-Apr;24(2):155-64.
74. Orditura M, Galizia G, Napolitano V, Martinelli E, Pacelli R, Lieto E, Aurilio G, Vecchione L, Morgillo F, Catalano G, Ciardiello F, Del Genio A, Di Martino N, De Vita F. Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. *Cancer Invest.* 2010 Oct;28(8):820-7.
75. Morgillo F, D'Aiuto E, Troiani T, Martinelli E, Cascone T, De Palma R, Orditura M, De Vita F, Ciardiello F. Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. *Lung Cancer.* 2011 Mar;71(3):283-90.
76. Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. *Clin Cancer Res.* 2010 Oct 15;16 (20):4990-5001.

77. Lieto E, Orditura M, Castellano P, Pinto M, Zamboli A, De Vita F, Pignatelli C, Galizia G. Endoscopic intraoperative anastomotic testing may avoid early gastrointestinal anastomotic complications. A prospective study. *J Gastrointest Surg.* 2011 Jan;15(1):145-52.
78. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. *Cancer Treat Rev.* 2010 Nov; 36; 3:11-5.
79. Giuliani F, De Vita F, Colucci G, Pisconti S. Maintenance therapy in colon cancer. *Cancer Treat Rev.* 2010 Nov; 36;3:42-5.
80. Silvestris N, Maiello E, De Vita F, Cinieri S, Santini D, Russo A, Tommasi S, Azzariti A, Numico G, Pisconti S, Petriella D, Lorusso V, Millaku A, Colucci G. Update on capecitabine alone and in combination regimens in colorectal cancer patients. *Cancer Treat Rev.* 2010 Nov; 36; 3:46-55.
81. De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, Pinto C, Di Maio M, Farella A, Troiani T, Morgillo F, Napolitano V, Ancona E, Di Martino N, Ruol A, Galizia G, Del Genio A, Ciardiello F. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. *Br J Cancer.* 2011 Feb 1;104(3):427-32.
82. Andolfo I, Petrosino G, Vecchione L, De Antonellis P, Capasso M, Montanaro D, Gemei M, Troncone G, Iolascon A, Orditura M, Ciardiello F, De Vita F, Zollo M. Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. *BMC Cancer.* 2011 Apr 11;11:126.
83. De Vita F, Giordano G, Fabozzi A, Guerrera B, Fabozzi T, Fasano M, Ferrara M, Fascione A, Di Benedetto G. Metastatic melanoma: an unusual presentation. *Tumori.* 2011 Jan-Feb;97(1):130-2.
84. Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F. Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. *Dis Esophagus.* 2012 Feb;25(2):130-6.
85. Sellitto A, Galizia G, De Fanis U, Lieto E, Zamboli A, Orditura M, De Vita F, Giunta R, Lucivero G, Romano C. Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. *J Clin Immunol.* 2011 Dec;31(6):1095-104.

86. Galizia G, Castellano P, Pinto M, Zamboli A, Orditura M, De Vita F, Pignatelli C, Lieto E. Radiofrequency-assisted liver resection with a comb-shaped bipolar device versus clamp crushing: a clinical study. *Surg Innov.* 2012 Dec;19(4):407-14.

87. Morgillo F, Martinelli E, Troiani T, Orditura M, De Vita F, Ciardiello F. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. *PLoS One.* 2011;6(12):e28841.

88. Galizia G, Gemei M, Del Vecchio L, Zamboli A, Di Noto R, Mirabelli P, Salvatore F, Castellano P, Orditura M, De Vita F, Pinto M, Pignatelli C, Lieto E. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. *Arch Surg.* 2012 Jan;147(1):18-24.

89. Galizia G, Napolitano V, Castellano P, Pinto M, Zamboli A, Schettino P, Orditura M, De Vita F, Auricchio A, Mabilia A, Pezzullo A, Lieto E. The Over-The-Scope-Clip (OTSC) system is effective in the treatment of chronic esophagojejunal anastomotic leakage. *J Gastrointest Surg.* 2012 Aug;16(8):1585-9.

90. Silvestris N, Del Re M, Azzariti A, Maiello E, Lombardi L, Cinieri S, Guarini A, Brunetti AE, Delcuratolo S, De Vita F, Pisconti S, Danesi R, Colucci G. Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. *Expert Opin Ther Targets.* 2012 Apr;16; 2:111-7.

91. De Vita F, Giuliani F, Silvestris N, Rossetti S, Pizzolorusso A, Santabarbara G, Galizia G, Colucci G, Ciardiello F, Orditura M. Current status of targeted therapies in advanced gastric cancer. *Expert Opin Ther Targets.* 2012 Apr; 16; 2:29-34.

92. Troiani T, Martinelli E, Capasso A, Morgillo F, Orditura M, De Vita F, Ciardiello F. Targeting EGFR in pancreatic cancer treatment. *Curr Drug Targets.* 2012 Jun;13(6):802-10.

93. Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. *Expert Opin Investig Drugs.* 2012 Jul;21(7):949-59.

94. Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-

negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. *BMC Cancer*. 2012 Oct 19;12:482.

95. Iovino F, Auriemma PP, Viscovo LD, Scagliarini S, Di Napoli M, De Vita F. Persistent left superior vena cava: a possible contraindication to chemotherapy and total parenteral nutrition in cancer patients. *Oncol Lett*. 2012 Oct;4(4):759-762.

96. Martinelli E, Troiani T, Morgillo F, Orditura M, De Vita F, Belli G, Ciardiello F. Emerging VEGF-receptor inhibitors for colorectal cancer. *Expert Opin Emerg Drugs*. 2013 Mar;18(1):25-37.

97. Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. *Clin Cancer Res*. 2013 May 21.

98. Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C. Sorafenib: from literature to clinical practice. *Ann Oncol*. 2013 Apr; 24; 2:30-37.

99. Galizia G, Gemei M, Orditura M, Romano C, Zamboli A, Castellano P, Mabilia A, Auricchio A, De Vita F, Del Vecchio L, Lieto E. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. *J Gastrointest Surg* 2013; Jun 28.

100. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus Bevacizumab. *PloS One* Jul 2013.

101. Morgillo F, De Vita F, Orditura M, Antonioli G, Auriemma P, Diadema MR, Lieto E, Savastano B, Festino L, Laterza MM, Fabozzi A, Ventriglia J, Petrillo A, Ciardiello F, Barbarisi A, Iovino F. Serum Insulin like Growth Factor I (IGF-1) levels correlate with the risk of node metastasis in endocrine positive breast cancer. *Current Oncology* 2013 Aug;20(4): 283-8.

102. Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Barni S, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Di Costanzo F, Comandone A, Maiello E, Numico G, Berardi S, Leo S, Angelini F, Cinieri S, Russo A, Brunetti AE, Santini D. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. *PloS One* 2013.

103. Orditura M, Galizia G, Fabozzi A, Lieto E, Gambardella V, Morgillo F, Del Genio GM, Fei L, Di Martino N, Renda A, Ciardiello F, De Vita F. Preoperative treatment of locally advanced esophageal carcinoma (Review). *Int J Oncol*. 2013 Dec;43(6):1745-53.

104. Galizia G, De Vita F, Lieto E, Zamboli A, Morgillo F, Castellano P, Mabilia A, Auricchio A, Renda A, Ciardiello F, Orditura M. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. *Oncol Rep*. 2013 Dec;30(6):2992-8.

105. Marano L, Izzo G, Esposito G, Petrillo M, Cosenza A, Marano M, Fabozzi A, Boccardi V, De Vita F, Di Martino N. Peripherally inserted central catheter tip position: a novel empirical-ultrasonographical index in a modern surgical oncology department. *Ann Surg Oncol*. 2014 Feb;21(2):656-61.

106. Galizia G, Lieto E, De Vita F, Ferraraccio F, Zamboli A, Mabilia A, Auricchio A, Castellano P, Napolitano V, Orditura M. Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. *Int J Colorectal Dis*. 2014 Jan;29(1):89-97.

107. Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. *Eur J Cancer* 2014 Jan;50(2):277-89.

108. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F. Treatment of gastric cancer. *World J Gastroenterol* 2014 February 21; 20(7): 1635-1649.

109. De Vita F, Ventriglia J, Laterza M, Fabozzi A, Ciardiello F, Orditura M. Ramucirumab: a new option in advanced gastric cancer. *Eur J Oncol* 2014,19:30-32.

110. Orlando L, Giotta F, Lorusso V, De Vita F, Filippelli G, Maiello E, Riccardi F, Pappagallo GL, Fedele P, Gebbia N, Verderame F, Barni S, Blasi L, Pisconti S, Colucci G, Cinieri S. Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. *Future Oncol*. 2014 Apr;10(5):725-33.

111. Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Renda A,

Ciardello F, De Vita F. Effect of preoperative chemo-radiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma. A pilot study. *Current Oncology* 2014 21(3):125-33.

112. Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio AM, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. *Ann Oncol.* 2014 Jun 18. pii: mdu230.

113. De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M. Clinical management of advanced gastric cancer: Role of new molecular drugs. *World J Gastroenterol.* 2014 Oct 28;20(40):14537-58.

114. Federico A, Orditura M, Cotticelli G, De Sio I, Gaeta L, Zulli C, Fabozzi A, Ciardiello F, Loguercio C, De Vita F. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrosi. *Oncol Lett* 2015 Apr;9(4):1628-1632.

115. Galizia G, Lieto E, De Vita F, Castellano P, Ferraraccio F, Zamboli A, Mabilia A, Auricchio A, De Sena G, De Stefano L, Cardella F, Barbarisi A, Orditura M. Modified versus standard D2 lymphadenectomy in total gastrectomy for non junctional gastric carcinoma with lymph node metastasis. *Surgery.* 2015 Feb; 157(2):285-96.

116. Lieto E, Galizia G, Orditura M, Romano C, Zamboli A, Castellano P, Mabilia A, Auricchio A, De Vita F, Gemei M. CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence. *Oncol Lett.* 2015 Feb;9(2):542-550.

116. Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, Della Corte CM, De Vita F. Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. *Oncol Lett.* 2015 Mar;9(3):1403-1405.

117. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. *Mol Ther Nucleic Acids.* 2015 Mar 17;4:e233.



118. Galizia G, Lieto E, Zamboli A, De Vita F, Castellano P, Romano C, Auricchio A, Cardella F, De Stefano L, Orditura M. Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. *Surgery* 2015 Jul;158(1):112-20.
119. Orditura M, Galizia G, Lieto E, De Vita F, Ciardiello F. Treatment of esophagogastric junction carcinoma: an unsolved debate. *World J Gastroenterol.* 2015 Apr 21;21(15):4427-31.
120. Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A. c-Met targeting in advanced gastric cancer: An open challenge. *Cancer Lett* 2015 Aug 28;365(1):30-6.
121. Conzo G, Gambardella C, Tartaglia E, Sciascia V, Mauriello C, Napolitano S, Orditura M, De Vita F, Santini L. Pancreatic fistula following pancreatoduodenectomy. Evaluation of different surgical approaches in the management of pancreatic stump. Literature review. *Int J Surg* 2015 Sep; 21 Suppl 1:S4-9.
121. Mauriello C, Napolitano S, Gambardella C, Candela G, De Vita F, Orditura M, Sciascia V, Tartaglia E, Lanza M, Santini L, Conzo G. Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review. *Int J Surg.* 2015 Sep;21 Suppl 1:S10-4.
123. Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. *Oncotarget.* 2016 Jan 26;7(4):4265-78.
124. Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, De Vita F. Pancreatic neuroendocrine tumors: Nosography, management and treatment. *Int J Surg.* 2016 Apr;28 Suppl 1:S156-62.
125. Ciardiello F, Normanno N, Martinelli E, Troiani T, Piscanti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E; CAPRI-GOIM investigators. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. *Ann Oncol.* 2016 Jun;27(6):1055-61.
126. Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or

gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *Int J Cancer*. 2016 Dec 15;139(12):2859-2864.

127. De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. *BMC Cancer*. 2016 Sep 2;16(1):709.

128. D'Aniello C, Vitale MG, Farnesi A, Calvetti L, Laterza MM, Cavaliere C, Della Pepa C, Conteduca V, Crispo A, De Vita F, Grillone F, Ricevuto E, De Tursi M, De Vivo R, Di Napoli M, Cecere SC, Iovane G, Amore A, Piscitelli R, Quarto G, Pisconti S, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Naglieri E, Galli L, Carteni G, De Giorgi U, Pignata S, Facchini G, Rossetti S. Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. *Front Pharmacol*. 2016 Sep 28;7:331.

129. Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, Iovino F, Romano C, Morgillo F, Mosca L, Diadema MR, Lieto E, Procaccini E, De Vita F, Ciardiello F. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. *ESMO Open* 2016 Mar 7;1(2):e000038.

130. Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F (2016). Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. *Oncol Lett* 2016 Dec;12(6):4505-4509.

131. Mauriello C, Polistena A, Gambardella C, Tartaglia E, Orditura M, De Vita F, Santini L, Avenia N, Conzo G. Pancreatic stump closure after pancreatoduodenectomy in elderly patients: a retrospective clinical study. *Aging Clin Exp Res* 2017 Feb; 29(Suppl 1):35-40.

132. Panarese I, De Vita F, Ronchi A, Romano M, Alfano R, Di Martino N, Zito Marino F, Ferraraccio F, Franco R. Predictive biomarkers along gastric cancer pathogenetic pathways. *Expert Rev Anticancer Ther* 2017 May;17(5):417-425.

133. Fasano M, Fabozzi A, Giordano G, Venturini F, Aurilio G, Cantile F, Fabozzi T, Ricci V, Santabarbara G, Morgillo F, Ciardiello F, De Vita F. Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report. *Oncol Lett* 2017 Feb;13(2):979-983.

134. Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Diana A, Castellano P, De Vita F, Orditura M. Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience. *PLoS One* 2017 Apr 5;12(4):e0173619.
135. Rossetti S, D'Aniello C, Iovane G, Scagliarini S, Laterza MM, De Vita F, Savastano C, Carteni G, Porricelli MA, Berretta M, Pisconti S, Facchini G, Cavaliere C. Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma. *Front Pharmacol.* 2017 Jul 20;8:484.
136. Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. *ESMO Open.* 2017 Feb 20;1(6):e000086.
137. Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017 Nov;18(11):1467-1482.
138. Laterza MM, Pompella L, Petrillo A, Tirino G, Pappalardo A, Orditura M, Troiani T, Ciardiello F, Di Martino N, De Vita F. Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. *Med Oncol.* 2017 Oct 17;34(11):186.
139. Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, De Vita F, Ciardiello F, Orditura M. Phosphatidylinositol 3-kinase (PI3K $\alpha$ )/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. *Oncotarget* 2017 Aug 22;8(44):76479-76491.
140. Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, Reginelli A, Bisceglie MD, Latiano TP, Maiello E, Orditura M, De Vita F, Morgillo F, Ciardiello F, Troiani T (2017). Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. *ESMO Open* 2017 Jul 29;2(3):e000177.

141. Sellitto A, Adinolfi LE, Romano C, Iovino F, Auriemma PP, Russo D, De Vita F. Plantar Kaposi Sarcoma Revealed by Antisynthetase Syndrome. *J Clin Rheumatol* 2017 Dec 12.
142. Pietrantonio F, Fucà G, Morano F, Glohini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. *Clin Cancer Res* 2018 Mar 1;24(5):1082-1089.
143. Tehfe M, Tabchi S, Laterza MM, De Vita F. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance. *Future Oncol* 2018 Feb;14(3):223-228.
144. Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. *Target Oncol*. 2018 Mar 27.
145. Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. *Pancreas*. 2018 Jul;47(6):759-771.
146. Petrillo A, Laterza MM, Tirino G, Pompella L, Ventriglia J, Pappalardo A, Famiglietti V, Martinelli E, Ciardiello F, Orditura M, Galizia G, De Vita F. Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. *Future Oncol*. 2018 Oct;14(24):2493-2505.
147. Ventriglia J, Petrillo A, Huerta Alvaro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. *Gastroenterol Res Pract*. 2018 Jun 10;2018:2373868.
148. Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F,

Morgillo F. Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs Breast. 2018 Oct;41:165-171.

149. Diana A, Franzese E, Centonze S, Carlino F, Della Corte CM, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. Curr Oncol Rep. 2018 Aug 20;20(10):76.

150. Pietrantonio F, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Nigro M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G. Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. Oncology. 2018 Aug 21:1-9.

151. Tirino G, Pompella L, Petrillo A, Laterza MM, Pappalardo A, Caterino M, Orditura M, Ciardiello F, Galizia G, De Vita F. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. Int J Mol Sci. 2018 Sep 7;19(9).